Neil Osterweil

1 week ago | oncologynewscentral.com | Neil Osterweil

The theme for the 2025 American Association for Cancer Research (AACR) Annual Meeting, to be held at the McCormick Place Convention Center in Chicago April 25–30, is “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact.”Program Committee Chairs Lillian L.

1 week ago | medicalnewsinsider.substack.com | Neil Osterweil

Imagine if your car could fix itself while you’re driving it—sealing oil leaks, tightening drive belts, re-inflating tires—all occurring as you zip along at highway speeds, oblivious to the continuous repair process. DNA does just that for human cells, activating nearly 550 genes that produce proteins to zoom in and repair anywhere from around 10,000 to 1,000,000 molecular lesions (think of them as DNA bruises) that occur in .

3 weeks ago | oncologynewscentral.com | Neil Osterweil

For patients with unresectable EGFR-mutated non-small cell lung cancer (NSCLC) who do not have disease progression after definitive chemoradiotherapy (CRT), maintenance therapy with osimertinib (Tagrisso) significantly delays the time to first subsequent therapy and shows favorable but not statistically significant survival trends, according to an updated analysis from the LAURA trial. Suresh S.

3 weeks ago | oncologynewscentral.com | Neil Osterweil

KRAS mutations occur in as many as 30% of non-small cell lung cancers (NSCLC) and were once considered “undruggable.” However, updated results from the phase 2 KROCUS trial suggest that a first-line combination consisting of the investigational KRAS G12c inhibitor fulzerasib (Dupert) plus the EGFR-targeting antibody cetuximab (Erbitux) is associated with a high and durable objective response rate (ORR) and is well-tolerated.

3 weeks ago | oncologynewscentral.com | Neil Osterweil

What is the next step for patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease has progressed on first-line osimertinib (Tagrisso), but who have no identifiable biomarkers to guide second-line therapy? Early results from the phase 2 ORCHARD platform study suggest that the next step could be adding the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd; Datroway) to osimertinib.